XEN1101 for Major Depressive Disorder

Summary

This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener XEN1101 (Xenon Pharmaceuticals).

Timeline

Start

2021-10-19

Primary completion

2024-10-03

Completion

2024-11-07

Publications

• Murrough J, Fremont R, Neukam P, Govindarajulu U, Ables J, Hameed S, Corwin M, Hargrove M, Chang H, Boukezzi S, Kelly C, Swann A, Salas R, Amarneh D, Engelhardt J, Weyland A, Bagiella E, Morris L, Mathew S. A Randomized, Controlled Trial of the Novel, Potent Kv7 Channel Opener Azetukalner in Individuals with Major Depressive Disorder and Anhedonia: Neural Response to Reward, Clinical Outcomes, and Safety. Res Sq [Preprint]. 2025 Sep 15:rs.3.rs-7448148. doi: 10.21203/rs.3.rs-7448148/v1.

Drugs

Indications